3.229.124.74
dgid:
enl:
npi:0
Autoimmune
Conference Roundup

Data from Trial Evaluating Eculizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder to be Presented at AAN Annual Meeting

Posted on

Alexion Pharmaceuticals, Inc, announced that nine abstracts have been accepted for presentation at the 72nd annual meeting of the American Academy of Neurology (AAN) in Toronto, Ontario, Canada from April 25 through May 1, 2020. Long-term safety and efficacy results from the Phase 3 PREVENT study and open-label extension of SOLIRIS® (eculizumab) in adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive will be presented, demonstrating the percentage of SOLIRIS patients who were relapse-free remained high (94 percent) through 192 weeks. Additional PREVENT data to be presented highlight the efficacy of SOLIRIS and its impact on health outcomes, hospitalization rates and relapse treatment, disability worsening and quality of life, and the evidence of benefit of SOLIRIS across a broad range of patients with NMOSD.

The accepted abstracts are listed below and are now available on the AAN website:

Oral Presentations

Long-Term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder. Oral presentation during session S34: Clinical Trials and Therapeutics in Autoimmune Neurology, April 28, 2020, 4:30 p.m. ET.

Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from the Phase 3 PREVENT Study. Oral presentation during session S34: Clinical Trials and Therapeutics in Autoimmune Neurology, April 28, 2020, 4:18 p.m. ET.

Poster Presentations

Impact of Eculizumab on Health Outcomes in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Findings from the PREVENT Study. Poster presentation during session P14: Autoimmune Neurology: NMOSD and MOG 2, April 30, 2020, 8:00 – 9:00 a.m. ET and session P17: Neuroinflammation, May 1, 2020, 11:30 a.m. – 1:00 p.m. ET.

Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: the Phase 3 PREVENT Study. Poster presentation during session P14: Autoimmune Neurology: NMOSD and MOG 2, April 30, 2020, 8:00 – 9:00 a.m. ET and session P17: Neuroinflammation, May 1, 2020, 11:30 a.m. – 1:00 p.m. ET.

Impact of Eculizumab on Disability Worsening and Quality of Life in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Results from the Phase 3 PREVENT Study. Poster presentation during session P14: Autoimmune Neurology: NMOSD and MOG 2, April 30, 2020, 8:00 – 9:00 a.m. ET and session P17: Neuroinflammation, May 1, 2020, 11:30 a.m. – 1:00 p.m. ET.

Infection Risk in Patients with Complement-Mediated Neurological Disorders Receiving Eculizumab: Findings from Two Phase 3 Studies and Their Extensions in Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (AQP4+ NMOSD) and Acetylcholine-Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis (AChR+ gMG). Poster presentation during session P14: Autoimmune Neurology: NMOSD and MOG 2, April 30, 2020, 8:00 – 9:00 a.m. ET.

The Impact of Relapses on Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder: Data from the Phase 3 PREVENT Study. Poster presentation during session P14: Autoimmune Neurology: NMOSD and MOG 2, April 30, 2020, 8:00 – 9:00 a.m. ET.

Benefit of Eculizumab for a Broad Range of Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study. Poster presentation during session P14: Autoimmune Neurology: NMOSD and MOG 2, April 30, 2020, 8:00 – 9:00 a.m. ET and session P17: Neuroinflammation, May 1, 2020, 11:30 a.m. – 1:00 p.m. ET.

Neuromyelitis Optica Spectrum Disorder (NMOSD): Epidemiology, Treatments, and Outcomes in a Single Center. Poster presentation during session P14: Autoimmune Neurology: NMOSD and MOG 2, April 30, 2020, 8:00 – 9:00 a.m. ET.

Read the full press release here.

Source: Alexion Pharmaceuticals, Inc.
-Advertisement-
Related Articles
FDA Grants DSG3-CAART Orphan Drug Designation for the Treatment of Pemphigus Vulgaris
May 31, 2021
Part 1 Results from PIONEER Trial in Indolent Systemic Mastocytosis Announced
Mar 16, 2020
AAAI Cancels Annual Meeting
Mar 14, 2020
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-